252254 Additionally, the aging process of various organs exhibits variability, as demonstrated by the UK Biobank trial, which adds complexity to the impact of GLP-1 RAs and underscores the importance of personalized treatment
For a 58-year-old with a 10-year ASCVD risk of 12%, these transient changes warrant discussion but rarely prohibit treatment
NB: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing review & editing
There are multiple strategies aimed at extending the half-life of GLP-1 and enhancing its efficacy (as shown in Figure 1) [1]
Semaglu-0.25/0.5 (2mg/3ml) Pfp Injection 1's is available in a pre-filled multi-dose pen that allows flexible dosing